1,063 Shares in Cencora, Inc. (NYSE:COR) Purchased by Enterprise Bank & Trust Co

Enterprise Bank & Trust Co purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,063 shares of the company’s stock, valued at approximately $239,000.

Several other institutional investors have also added to or reduced their stakes in COR. Insight Wealth Strategies LLC lifted its stake in shares of Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares during the last quarter. Cerity Partners LLC raised its position in shares of Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after acquiring an additional 3,610 shares in the last quarter. Portfolio Design Labs LLC bought a new position in shares of Cencora in the 3rd quarter worth $1,404,000. Mackenzie Financial Corp increased its position in Cencora by 9.9% during the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock valued at $18,250,000 after buying an additional 7,266 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Cencora by 40.2% during the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock valued at $243,173,000 after buying an additional 308,773 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR traded down $0.47 during midday trading on Monday, reaching $235.72. 459,054 shares of the stock were exchanged, compared to its average volume of 1,248,639. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business’s 50-day moving average price is $237.77 and its 200 day moving average price is $233.48. The company has a market capitalization of $45.56 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.93%. Cencora’s payout ratio is 29.29%.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 94,696 shares of company stock worth $22,862,734. Insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. UBS Group increased their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Finally, Wells Fargo & Company lowered their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.